氟马替尼二线治疗老年慢性髓性白血病的疗效及影响因素分析

doi:10.3969/j.issn.1003-9198.2025.01.016

Abstract

Abstract: Objective To analyze the efficacy and influencing factors of flumatinib as second-line treatment for elderly patients with chronic myeloid leukemia in chronic phase(CML-CP). Methods A retrospective study including 25 elderly CML-CP patients who received flumatinib as a second-line drug for more than 3 months in our hospital from 2020 to 2023 was conducted, and the efficacy and influencing factors were analyzed. Results A total of 25 patients who failed first-line imatinib treatment were collected, with a median follow-up of 24 (2-48) months, 22 (88.0%) patients obtained complete hematological response(CHR)and 10 (40.0%) patients obtained major molecular response(MMR). Univariate analysis showed that Sokal score was a factor influencing patients to obtain MMR; Sokal score, duration of imatinib treatment and pretreatment resistance status were influencing factors of CCyR. The median progression-free survival(PFS)and overall survival(OS)were 19.4 months and 22.5 months, respectively. The incidence rate of hematologic adverse events was 28.0% (7/25) and the incidence rate of non-hematologic adverse events was 20.0% (5/25). Conclusions Flumatinib is safe and effective in the second-line treatment of CML-CP in the elderly.

Key words: chronic myeloid leukemia, aged, flumatinib, efficacy

CLC Number:

R 557

ZHANG Siqi, SUN Xiaoxing, YANG Shili, GE Hongfeng, FENG Jiangzhou. Analysis of the efficacy and factors affecting the second-line treatment of chronic myeloid leukemia in the elderly receiving flumatinib[J]. Practical Geriatrics, 2025, 39(1): 70-73.

References

[1] ÓBRIEN S, BERMAN E, BORGHAEI H, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia[J]. J Natl Compr Canc Netw, 2009, 7(9):984-1023.
[2] HOCHHAUS A, LARSON R A, GUILHOT F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia[J]. N Engl J Med, 2017, 376(10):917-927.
[3] MULLER M C. New drug for chronic myeloid leukemia might stimulate the market[J]. Clin Cancer Res, 2021, 27 (1): 3-4.
[4] ZHANG L, MENG L, LIU B, et al. Flumatinib versus Imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label, multi-center FESTnd study[J]. Clin Cancer Res, 2021, 27(1):70-77.
[5] 中华医学会血液学分会. 慢性髓性白血病中国诊断与治疗指南(2020年版)[J]. 中华血液学杂志, 2020, 41(5):353-364.
[6] FAIRCHILD A T, TANKSLEY J P, TENENBAUM J D, et al. Interrater reliability in toxicity identification: limitations of current standards[J]. Int J Radiat Oncol Biol Phys, 2020, 107(5):996-1000.
[7] SHAH N P, ROUSSELOT P, SCHIFFER C, et al. Dasatinib in imatinib-resistant or-intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034[J]. Am J Hematol, 2016, 91(9):869-874.
[8] KANTARJIAN H M, HUGHES T P, LARSON R A, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis[J]. Leukemia, 2021, 35 (2): 440-453.
[9] HEHLMANN R, LAUSEKER M, SAUßELE S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study Ⅳ and impact of non-CML determinants[J]. Leukemia, 2017, 31 (11): 2398-2406.
[10] KALMANTI L, SAUSSELE S, LAUSEKER M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study Ⅳ[J]. Leukemia, 2015, 29 (5): 1123-1132.
[11] YANG M, XI Q, JIA W, et al. Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants[J]. Bioorg Med Chem Lett, 2019, 29 (24): 126758.
[12] GAO H, LI L, MU J, et al. Efficacy of Flumatinib in CML patients with F359V/C mutation[J].Indian J Hematol Blood Transfus, 2023, 39(2):344-346.
[13] LI Z, MENG L, ZHANG Y, et al. Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: results from the China randomized phase Ⅲ study[J]. J Clin Oncol, 2019, 37 (15_suppl): 7004.
[14] 张小帅, 刘兵城, 杜新, 等. 氟马替尼与伊马替尼治疗初发慢性髓性白血病慢性期患者的有效性及严重血液学不良反应发生率比较[J]. 中华血液学杂志, 2023, 44(9):728-736.
[15] LUO H, QUAN H, XIE C, et al. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance[J]. Leukemia, 2010, 24 (10): 1807-1809.
[16] HUANG J, XIAO J, HE L, et al. Overcoming flumatinib resistance in chronic myeloid leukaemia: insights into cellular mechanisms and ivermectin’s therapeutic potential[J]. J Cell Mol Med, 2024, 28(14): e18539.

Analysis of the efficacy and factors affecting the second-line treatment of chronic myeloid leukemia in the elderly receiving flumatinib

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 0

[1]	WANG Xue, ZHANG Zhenyong, XU Bin, ZHU Ya, ZHOU Xuan, ZHANG Yongjia, ZHUANG Ruijuan. Study on association of serum levels of VEGF and BDNF with severity of vascular dementia and predictive value for prognosis [J]. Practical Geriatrics, 2025, 39(1): 32-36.
[2]	LIU Chuan, PAN Yiming, YU Wenhua, ZHANG Wanshu, LI Jiatong, LI Xiaxia, XING Yiwen, LI Jing, MA Lina. Reliability and validity of the Clinical pHysical rEsilience assEssment Scale (CHEES) in elderly inpatients [J]. Practical Geriatrics, 2025, 39(1): 37-40.
[3]	ZHOU Jing, SUN Luoyang, WANG Ling, MA Jiaxu. Effects of erector spinae plane block combined with stellate ganglion block in elderly patients undergoing total laparoscopic hysterectomy [J]. Practical Geriatrics, 2025, 39(1): 51-55.
[4]	WANG Meijuan, JIANG Xuezhong, WANG Hui, LIU Xiaojing, PANG Huiyan. Application value of two-dimensional speckle tracking imaging in assessing arterial function in overweight elderly with normal carotid artery structure [J]. Practical Geriatrics, 2025, 39(1): 56-60.
[5]	YIN Pengcheng, WANG Xinzhi, ZHANG Linzhong. Study on nonlinear analysis of EEG related to memory ability in elderly patients [J]. Practical Geriatrics, 2025, 39(1): 61-65.
[6]	LI Ting, PEI Junfang, SUN Shanshan. Drug resistance of pathogenic bacteria and effects of drug resistance degree on serum levels of IL-6, IL-10 and CRP in elderly patients with pulmonary infection [J]. Practical Geriatrics, 2025, 39(1): 83-87.
[7]	WU Wangyi, ZHAO Chunyan, SUN Yuxiao. Effects of different dietary structures on postprandial hypotension after breakfast in elderly patients with hypertension [J]. Practical Geriatrics, 2025, 39(1): 88-92.
[8]	SONG Chengya, YANG Ying, HONG Kan. Effect and mechanism of short-chain fatty acids on sarcopenia in elderly patients complicated with type 2 diabetes mellitus [J]. Practical Geriatrics, 2025, 39(1): 98-101.
[9]	LI Jiang, QIU Yan, WANG Ting, WANG Dan, YU Yifan, PU Lingli, BU Ling. Correlation between preoperative SII/ALB and clinicopathologic features in elderly patients with lung adenocarcinoma [J]. Practical Geriatrics, 2024, 38(9): 893-896.
[10]	DAI Jing, CUI Yan. Correlation between glycosylated hemoglobin variability and cognitive dysfunction in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(9): 931-935.
[11]	ZHENG Hong, QI Zhenbo, XU Peng, XU Jie, YU Xinyu, ZANG Yanan, ZHANG Zhaoyan. Effects of hypnotics on cognition function and daytime sleepiness in the elderly [J]. Practical Geriatrics, 2024, 38(9): 936-939.
[12]	ZHANG Xingxing, ZHANG Haiyang, HE Xiaojing, LU Xiang. Investigation on the relationship between different physical indexes and the risk of diabetes mellitus in the elderly [J]. Practical Geriatrics, 2024, 38(9): 940-943.
[13]	NI Hongyan, CHEN Yun, ZHANG Qibing, MA Yiming, XIE Chenglan. Effects of electroacupuncture on cognitive function and inflammatory factors in elderly patients undergoing lower limb orthopedic surgery during the perioperative period [J]. Practical Geriatrics, 2024, 38(9): 944-947.
[14]	LI Xiaomin, LI Xiaolin, LI Jie, WU Lei, HAO Ranran. Efficiency influencing factors of transanal double-balloon enteroscopy in elderly patients [J]. Practical Geriatrics, 2024, 38(9): 958-961.
[15]	CAI Huicui, CHEN Yan, WANG Yan, YE Jinjun, ZHU Yuying. Effects of diversified health education model with simple respiratory function exercise on cancer-related fatigue and compliance behavior in elderly patients with lung cancer receiving radiotherapy [J]. Practical Geriatrics, 2024, 38(9): 968-972.